Transaction · 0001995218-26-000017

Townsend Richard Nolan

Townsend Richard Nolan, CEO, reported a transaction classified as grant at Lexeo Therapeutics, Inc. involving 2306.000000 shares for an estimated $6097.06. Reported holdings after the transaction were 376778.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
LXEOLexeo Therapeutics, Inc.
Filing timeSep 28
Trade dateSep 14, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$4.18
Pre-filing
1mo ago +15.8%1w ago +16.7%1d ago +1.7%
Returns since
7d30d90d180d1y

LXEO price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
LXEO since 2026-09-28Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001995218-26-000017
Common Stock
Transaction date
Sep 14, 2026
Filed Sep 28, 2026, 09:15 PM · 14d delay
Shares
2.30k sh
$2.64 per share
Estimated value
$6.09k
Computed from shares × price
Holdings after
376k sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 14 calendar days after the transaction date.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Delayed Filing Direct Ownership
-22score
Filing-only score

-22

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exe…

  2. F2

    Includes 242,911 Restricted Stock Units.

  3. F3

    25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the…

Original filing · 0001995218-26-000017
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

LXEO